Serum antibody response to BNT162b2 after natural SARS-CoV-2 infection.
Adult
Age Factors
Antibodies, Viral
/ immunology
Antibody Formation
/ immunology
BNT162 Vaccine
COVID-19
/ immunology
COVID-19 Serological Testing
COVID-19 Vaccines
/ therapeutic use
Coronavirus Nucleocapsid Proteins
/ immunology
Female
Humans
Male
Middle Aged
Phosphoproteins
/ immunology
SARS-CoV-2
Spike Glycoprotein, Coronavirus
/ immunology
SARS-CoV-2
antibody response
serology
seropositive
vaccination
Journal
European journal of clinical investigation
ISSN: 1365-2362
Titre abrégé: Eur J Clin Invest
Pays: England
ID NLM: 0245331
Informations de publication
Date de publication:
Nov 2021
Nov 2021
Historique:
revised:
16
05
2021
received:
02
03
2021
accepted:
30
05
2021
pubmed:
3
8
2021
medline:
6
11
2021
entrez:
2
8
2021
Statut:
ppublish
Résumé
There is preliminary evidence that individuals with previous SARS-CoV-2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE-marked tests. This study aimed to close this gap. Sixty-nine seronegatives and 12 individuals post-SARS-CoV-2 infection (tested by CE-labelled Roche NC immunoassay or PCR-confirmed assay) were included 21 ± 1 days after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. Antibody response to viral spike protein (S) was assessed by CE-labelled Roche S and DiaSorin S1/S2 assays and by a surrogate virus neutralization test (sVNT). After a single dose of BNT162b2, individuals after natural SARS-CoV-2 infection presented with markedly higher anti-S levels than naïve individuals (Roche S: 9078.5 BAU/mL [5267.0-24 298.5] vs 79.6 [24.7-142.3]; and DiaSorin S1/S2: 1465.0 AU/mL [631.0-5365.0] vs 63.7 [47.8-87.5]) and showed all the maximum observed inhibition activity in the sVNT (98%), without overlaps between groups. There was a trend for higher responses in those with a more distant infection, although not statistically significant. The relative antibody increase after dose 2 was significantly higher among naïve individuals (25-fold), but antibody levels remained below that of seropositives. Compared with naïve individuals, seropositives after natural SARS-CoV-2 infection presented with a substantially higher antibody response already after dose 1 of BNT162b2, as measured by two CE-marked in vitro diagnostic tests and a sVNT. These results should stimulate discussion and research on whether individuals after previous SARS-CoV-2 infection would benefit from a two-part vaccination schedule or whether these currently much-needed second doses could be saved.
Sections du résumé
BACKGROUND
BACKGROUND
There is preliminary evidence that individuals with previous SARS-CoV-2 infections exhibit a more pronounced antibody response. However, these assumptions have not yet been supported by data obtained through various CE-marked tests. This study aimed to close this gap.
METHODS
METHODS
Sixty-nine seronegatives and 12 individuals post-SARS-CoV-2 infection (tested by CE-labelled Roche NC immunoassay or PCR-confirmed assay) were included 21 ± 1 days after receiving the first dose of the Pfizer/BioNTech BNT162b2 vaccine. Antibody response to viral spike protein (S) was assessed by CE-labelled Roche S and DiaSorin S1/S2 assays and by a surrogate virus neutralization test (sVNT).
RESULTS
RESULTS
After a single dose of BNT162b2, individuals after natural SARS-CoV-2 infection presented with markedly higher anti-S levels than naïve individuals (Roche S: 9078.5 BAU/mL [5267.0-24 298.5] vs 79.6 [24.7-142.3]; and DiaSorin S1/S2: 1465.0 AU/mL [631.0-5365.0] vs 63.7 [47.8-87.5]) and showed all the maximum observed inhibition activity in the sVNT (98%), without overlaps between groups. There was a trend for higher responses in those with a more distant infection, although not statistically significant. The relative antibody increase after dose 2 was significantly higher among naïve individuals (25-fold), but antibody levels remained below that of seropositives.
CONCLUSIONS
CONCLUSIONS
Compared with naïve individuals, seropositives after natural SARS-CoV-2 infection presented with a substantially higher antibody response already after dose 1 of BNT162b2, as measured by two CE-marked in vitro diagnostic tests and a sVNT. These results should stimulate discussion and research on whether individuals after previous SARS-CoV-2 infection would benefit from a two-part vaccination schedule or whether these currently much-needed second doses could be saved.
Identifiants
pubmed: 34337738
doi: 10.1111/eci.13632
pmc: PMC8420280
doi:
Substances chimiques
Antibodies, Viral
0
COVID-19 Vaccines
0
Coronavirus Nucleocapsid Proteins
0
Phosphoproteins
0
Spike Glycoprotein, Coronavirus
0
nucleocapsid phosphoprotein, SARS-CoV-2
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13632Informations de copyright
© 2021 The Authors. European Journal of Clinical Investigation published by John Wiley & Sons Ltd on behalf of Stichting European Society for Clinical Investigation Journal Foundation.
Références
Clin Chem. 2020 Nov 1;66(11):1405-1413
pubmed: 32777031
J Infect Dis. 2021 Feb 13;223(3):389-398
pubmed: 33140086
Trends Immunol. 2020 Nov;41(11):1006-1022
pubmed: 33041212
Biopreserv Biobank. 2018 Dec;16(6):477-482
pubmed: 30335475
Eur J Clin Invest. 2021 Apr;51(4):e13520
pubmed: 33583018
N Engl J Med. 2021 Feb 11;384(6):533-540
pubmed: 33369366
Nat Biotechnol. 2020 Sep;38(9):1073-1078
pubmed: 32704169
Eur J Clin Invest. 2010 Jan;40(1):35-53
pubmed: 20055895
BMJ. 2021 Feb 2;372:n308
pubmed: 33531333
Science. 2021 Jan 15;371(6526):288-292
pubmed: 33293339
Eur J Clin Invest. 2021 Nov;51(11):e13632
pubmed: 34337738
J Clin Microbiol. 2021 Mar 19;59(4):
pubmed: 33483360
Clin Chem. 2020 Aug 1;66(8):1104-1106
pubmed: 32484887
Sci Adv. 2021 Feb 3;7(6):
pubmed: 33536223
J Clin Microbiol. 2020 Aug 24;58(9):
pubmed: 32580948
Clin Infect Dis. 2021 Oct 5;73(7):e1830-e1840
pubmed: 33315061
Lancet. 2021 Mar 27;397(10280):1178-1181
pubmed: 33640037
Ther Deliv. 2021 Mar;12(3):235-244
pubmed: 33624533